News
Plus, news about Invivyd: Danaher’s tariffs hit: The life sciences company currently expects the costs of tariffs to be “something like $350 million” in 2025 … ...
John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Aside from his ...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can … ...
The planned exit of longstanding Pfizer CSO Mikael Dolsten comes at a pivotal moment for the huge drugmaker. The Covid-19 vaccine aura has fully worn … ...
The Biomedical Advanced Research and Development Authority (BARDA) has granted up to $453 million to Vaxart to revive its work on an oral Covid-19 vaccine … ...
Below are notable updates from the American Academy of Dermatology’s annual meeting over the weekend: ...
Novartis provided a peek Saturday of how it might expand development of its experimental drug remibrutinib, a BTK inhibitor being tested in a range of … ...
The team of German researchers who first reported clinical data backing the idea of using CAR-T cell therapies to treat autoimmune disorders has spelled out … ...
Pfizer’s latest two-at-once vaccination messaging taps into a holiday theme. A TV commercial and TikTok ad both celebrate “pie season” with the message that even … ...
As Eli Lilly launches its newly approved weight loss med Zepbound to much fanfare, Novo Nordisk is tossing a next-gen candidate in the ring. … ...
HHS on Friday announced its selections for the next-generation of Covid-19 vaccine candidates to receive $500 million in funding as part of the government’s Project … ...
When actor Bellamy Young was growing up, her father suffered from a brain disorder called hepatic encephalopathy (HE) caused by cirrhosis of the liver. … ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results